b.: 11926-068001 / 0009.CIP2

RECEIVED

NITED STATES PATENT AND TRADEMARK OFFICE

MAR 1 9 2002

Applicant: Vincent P. Stanton, Jr.

Art Unit : 1655

Serial No.: 09/648,123

Examiner: C. Wilder

TECH CENTER 1600/2900

Filed

: August 25, 2000

Title

: GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE

TREATMENT OF DISEASE, IN GENES RELATING TO DRUG PROCESSING

Commissioner for Patents Washington, D.C. 20231

RESPONSE

In response to the action mailed August 29, 2001, please amend the application as follows:

In the claims.

Please carcel claims 1-14.

Please add/claims 17-26.

- An isolated nucleic acid probe comprising at least 7 nucleotides which binds selectively to a variant human cytochrom&P-450 (CYP3A4) gene having a T to C variance at nucleotide 732 or a isolated nucleic acid probe completely complementary thereto.
 - 18. The probe of claim 17 wherein the probe comprises at least 15 nucleotides.
 - 19. The probe of claim 17 wherein the probe comprises at least 15 nucleotides.
 - 20. The probe of claim 17 wherein the probe comprises fewer than 200 nucleotides.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231

Signatu

Typed or Printed Name of Person Signing Certificate